Industry News

GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health

By Medimaging International staff writers
13 Nov 2021

Image: GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health (Photo courtesy of GE Healthcare)

General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.


The spin-off of GE Healthcare is a part of GE’s plan to form three industry-leading, global public companies focused on the growth sectors of aviation, healthcare, and energy. GE will combine GE Renewable Energy, GE Power, and GE Digital into one business that will be positioned to lead the energy transition, and then pursue a tax-free spin-off of this business in early 2024. Following these transactions, GE will be an aviation-focused company shaping the future of flight. As independently run companies, the businesses will be better-positioned to deliver long-term growth and create value for customers, investors, and employees.


“By creating three industry-leading, global public companies, each can benefit from greater focus, tailored capital allocation, and strategic flexibility to drive long-term growth and value for customers, investors, and employees. We are putting our technology expertise, leadership, and global reach to work to better serve our customers,” said GE Chairman and CEO H. Lawrence Culp, Jr. “Today is a defining moment for GE, and we are ready. Our teams have done exceptional work strengthening our financial position and operating performance, all while deepening our culture of continuous improvement and lean. And we’re not finished - we remain focused on continuing to reduce debt, improve our operational performance, and strategically deploy capital to drive sustainable, profitable growth. We have a responsibility to move with speed to shape the future of flight, deliver precision health, and lead the energy transition. The momentum we have built puts us in a position of strength to take this exciting next step in GE’s transformation and realize the full potential of each of our businesses.”


Related Links:
General Electric 



E-mail Print
FaceBook Twitter Google+ Linked in

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services. The company’s product areas include anesthesia delivery, diagnostic ECG, mammography, radiography, surgical imaging, maternal-infant care and clinical consumables.
More info

More articles about GE Healthcare

23 Dec 2021
GE Healthcare Completes Acquisition of BK Medical to Expand Its Ultrasound Business
GE Healthcare (Chicago, IL, USA) has completed its previously announced acquisition of BK Medical (Peabody, MA, USA; www.bkmedical.com) in a deal that would expand its ultrasound business from diagnostics into surgical and therapeutic interventions.
Read More
30 Sep 2021
GE Healthcare Acquires BK Medical to Expand Ultrasound Portfolio into Surgical Visualization
GE Healthcare (Chicago, IL, USA) has entered into an agreement to acquire BK Medical (Peabody, MA, USA) in a deal that is expected to create value by further strengthening BK, including through significant synergies with the benefit of GE’s technology and commercial scale.
Read More
26 Jul 2021
GE Healthcare Backs Development of Innovative Total-Body PET/CT Scanner for Simultaneous Whole-Body Imaging
GE Healthcare (Chicago, IL, USA) is backing a collaboration among Quibim (Valenciana, Spain), Full Body Insight, and Oncovision (Valenciana, Spain) to build an innovative total-body PET/CT scanner for simultaneous whole-body imaging.
Read More
30 Jan 2020
Study Finds Most Healthcare Institutions Plan to Use AI and Develop Own AI Algorithm
 A new study of healthcare professionals has revealed that Artificial Intelligence (AI) is widely expected to drive important benefits across the health system, from increasing efficiency to improving patient outcomes, but may also be the key to making healthcare more human. AI’s benefits range from increasing the amount of time clinicians can spend with patients and on cross-care team collaboration to enhancing the ability to deliver preventative care.
Read More
26 Sep 2019
GE Healthcare and Affibody Collaborate to Develop PET Imaging Tracers
GE Healthcare and Affibody AB have entered into a strategic collaboration to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1.
Read More
22 Aug 2019
GE Healthcare Partners with Fujitsu to Develop AI for Spotting Brain Aneurysms
GE Healthcare has entered into a research collaboration with Fujitsu Australia to diagnose and monitor brain aneurysms on scans faster and more efficiently by using artificial intelligence.
Read More
03 May 2019
First Deep Learning-Based Image Reconstruction Technology Receives FDA Clearance
GE Healthcare has received 510(k) clearance from the U.S. FDA for its Deep Learning Image Reconstruction (DLIR) engine on its new Revolution Apex CT device, and as an upgrade to its Revolution CT system in the U.S.
Read More
18 Oct 2018
GE Healthcare and ESR Enter AI Partnership for ECR 2019
GE Healthcare (Chicago, IL, USA) and the European Society of Radiology (Vienna, Austria) will be partnering on artificial intelligence (AI) for the upcoming European Congress of Radiology (ECR) to be held in Vienna, Austria on February 27-March 3, 2019. The partnership will include joint sessions on AI and a dedicated space at GE Healthcare’s booth where visitors will be able to experience the AI transformation through interactive tools.
Read More

Additional news

21 Jan 2022
Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases
The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.
Read More
21 Jan 2022
Global Digital X-Ray Systems Market to Be Driven by AI-Based Systems and Robotic Devices
The global digital X-ray systems market was valued at USD 11.74 billion in 2020 and is expected to grow at a CAGR of 7.45% during the forecast period 2021 to 2026, due to the rising number of cancer patients and increasing cases of orthopedic diseases/tumors, cardiovascular diseases (CVD), pneumonia, and dental disorders, among others.
Read More
20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; www.boehringer-ingelheim.com) to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Read More
20 Jan 2022
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Read More
18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions